Clinical features, testing, and management of patients with suspected prosthetic hip-associated cobalt toxicity: a systematic review of cases.
Safety concerns regarding cobalt-containing metal alloy hip prosthetics (Co-HP) have resulted in product recalls, a medical device alert, and issuance of guidance for clinicians. Recently, cases of suspected prosthetic hip-associated cobalt toxicity (PHACT) from Co-HP have been reported. Although little is known about suspected PHACT, these patients may be referred to medical toxicologists for evaluation and management recommendations. We searched MEDLINE, EMBASE, and unpublished abstracts from toxicology scientific meetings for references relevant to PHACT. Authors independently screened publications for inclusion criteria: publication in English, human study population, subject(s) are symptomatic (except for isolated hip pain), and cobalt values in any matrix (blood, serum, urine, CSF, synovial fluid) available for review. Data from 10 cases are reviewed. Patients with suspected PHACT had findings consistent with cobalt toxicity, including thyroid, cardiac, and neurologic dysfunction. Signs and symptoms appeared between 3 and 72 months after arthroplasty (median 19 months). Neurologic symptoms were most common. Ancillary testing varied considerably. All patients had elevated cobalt levels in one or more matrices. Enhanced elimination was attempted in 27 % of patients. At this time, the information currently available regarding patients with suspected PHACT is inadequate to guide clinical decision making. No consensus has been reached regarding the management of Co-HP patients with systemic symptoms. Indications for chelation have not been established and require further study. Improved case definitions, improved surveillance, and controlled studies are needed to elucidate the scope of this problem and guide future investigations.
Georgia Poison Center, 50 Hurt Plaza, Suite 600, Atlanta, GA, 30303, USA, jjdevli@emory.edu.
John J
JJ
Devlin
Adam C
AC
Pomerleau
Jeffrey
J
Brent
Brent W
BW
Morgan
Scott
S
Deitchman
Michael
M
Schwartz
D019644:Arthroplasty, Replacement, Hip / Q000009:adverse effects* / Q000295:instrumentation*; D015415:Biomarkers / Q000378:metabolism; D002614:Chelating Agents / Q000627:therapeutic use; D015913:Chelation Therapy; D003035:Cobalt / Q000378:metabolism / Q000506:poisoning*; D020878:Device Removal; D000075322:Heavy Metal Poisoning; D006622:Hip Prosthesis / Q000009:adverse effects*; D006801:Humans; D019216:Metals, Heavy / Q000378:metabolism; D011041:Poisoning / Q000175:diagnosis* / Q000209:etiology / Q000378:metabolism / Q000628:therapy*; D011237:Predictive Value of Tests; D011474:Prosthesis Design; D018570:Risk Assessment; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome
D015415:Biomarkers; D002614:Chelating Agents; D019216:Metals, Heavy; D003035:Cobalt